CCR2与冠状动脉疾病：西苏格兰冠心病预防研究的一项子研究
CCR2 and coronary artery disease: a woscops substudy.
作者信息
Dow David J, McMahon Alex D, Gray Ian C, Packard Chris J, Groot Pieter He
机构信息
GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, UK.
出版信息
BMC Res Notes. 2010 Feb 2;3:31. doi: 10.1186/1756-0500-3-31.
BACKGROUND
Several lines of evidence support a role for CCL2 (monocyte chemotactic protein-1) and its receptor CCR2 in the development of atherosclerosis. The aim of the present study was to determine the association of the CCR2 Val64Ile polymorphism with the development of coronary artery disease in the WOSCOPS study sample set.
FINDINGS
A total of 443 cases and 1003 controls from the West of Scotland Coronary Prevention Study (WOSCOPS) were genotyped for the Val64Ile polymorphism in the CCR2 gene. Genotype frequencies were compared between cases and controls. The CCR2 Val64Ile polymorphism was found not to be associated with coronary events in this study population (odds ratio 1.15, 95% CI 0.82-1.61, p = 0.41).
CONCLUSIONS
This case-control study does not support an association of the CCR2 Val64Ile polymorphism with coronary artery disease in the WOSCOPS sample set and does not confirm a possible protective role for CCR2 Val64Ile in the development of coronary artery disease.
背景
多项证据支持CCL2（单核细胞趋化蛋白-1）及其受体CCR2在动脉粥样硬化发展过程中发挥作用。本研究的目的是在西苏格兰冠心病预防研究（WOSCOPS）样本集中确定CCR2基因Val64Ile多态性与冠心病发展之间的关联。
研究结果
对来自西苏格兰冠心病预防研究（WOSCOPS）的443例病例和1003例对照进行CCR2基因Val64Ile多态性基因分型。比较病例组和对照组的基因型频率。在该研究人群中，发现CCR2 Val64Ile多态性与冠心病事件无关（比值比1.15，95%可信区间0.82 - 1.61，p = 0.41）。
结论
这项病例对照研究不支持在WOSCOPS样本集中CCR2 Val64Ile多态性与冠心病有关联，也未证实CCR2 Val64Ile在冠心病发展过程中可能具有的保护作用。
Zotero 插件